Genentech wins approval for new Herceptin indication

The FDA has approved Genentech's application to extend the approval for Herceptin to be used by women who have had initial therapy for breast cancer. Data suggests that Herceptin can reduce the recurrence of breast cancer by half. The agency approved Herceptin eight years ago as a treatment for advanced breast cancer.

- here's the AP report on Herceptin

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.